Sage Therapeutics (Sage Therapeutics) Days Sales Outstanding : 0.00 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Days Sales Outstanding?

Sage Therapeutics's average Accounts Receivable for the three months ended in Mar. 2024 was $0.00 Mil. Sage Therapeutics's Revenue for the three months ended in Mar. 2024 was $7.90 Mil. Hence, Sage Therapeutics's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Sage Therapeutics's Days Sales Outstanding or its related term are showing as below:

SAGE's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.66
* Ranked among companies with meaningful Days Sales Outstanding only.

Sage Therapeutics's Days Sales Outstanding stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Sage Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Sage Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Days Sales Outstanding Chart

Sage Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

Sage Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sage Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Sage Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sage Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sage Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Sage Therapeutics's Days Sales Outstanding falls into.

Sage Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Sage Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	86.455	*	365
=	0					/	86.455	*	365
=	0.00

Sage Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	7.902	*	365 / 4
=	0					/	7.902	*	365 / 4
=	0.00

Sage Therapeutics (NAS:SAGE) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Sage Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Sage Therapeutics (Sage Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (NAS:SAGE) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

SG7:Germany SG7:Germany

Address

215 First Street, Cambridge, MA, USA, 02142

Website

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

Executives

Elizabeth Barrett	director	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jessica Federer	director	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jeffrey M Jonas	director, officer: See Remarks	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Barry E Greene	director	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Laura Gault	officer: Chief Medical Officer	C/O SAGE THERAPEUTICS, INC., 245 FIRST STREET, SUITE 16, CAMBRIDGE MA 02142
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Benecchi	officer: Chief Commercial Officer	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
James M Frates	director	88 SIDNEY ST, CAMBRIDGE MA 021394136
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Albert Robichaud	officer: Chief Scientific Officer	215 FIRST STREET, CAMBRIDGE MA 02142
Michael Cloonan	officer: Chief Business Officer	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Anne Marie Cook	officer: General Counsel	101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Steven M Paul	director	C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Kimi Iguchi	officer: See Remarks	100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035